d2l

Risperidone (R 64 766) is a selective blocker of dopamine D2 receptors and serotonin 5-HT2 receptors that act as an atypical antipsychotic agent.

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Brexpiprazole (OPC-34712) is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Brexpiprazole S-oxide (DM-3411), a primary metabolite of Brexpiprazole, acts as a partial agonist of human 5-HT1A and dopamine receptors with Ki values of 0.12 nM and 0.3 nM, respectively.

Aripiprazole (OPC-14597) is an antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.

ONC206, an analogue of the TRAIL inducer ONC201, acts as a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations and possesses broad-spectrum anti-tumor activity.

BL-1020 Mesylate (CYP-1020 Mesylate) is an orally available GABA A receptor agonist and D2 antagonist that decreases dopamine activity and enhances GABAA activity.BL-1020 Mesylate has been used in the study of schizophrenia, Alzheimer's disease, and bi-directional cognitive impairment.

Brexpiprazole HCl (OPC 34712 dihydrochloride) is a new antipsychotic drug.

TH9028 TFA is an effective MTHFD2 inhibitor (IC50=11 nM) that suppresses proliferation in HL-60 cells, AML cells, and T-ALL Jurkat cells.

Perphenazine (Trilafon) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.

TH9028 is an inhibitor targeting MTHFD1, MTHFD2, and MTHFD2L, with IC50 values against the human-derived targets of 0.5 nM (MTHFD1), 11 nM (MTHFD2), and 27 nM (MTHFD2L), respectively. This compound binds to the substrate-binding region of the target enzymes, forming hydrogen bonds and other interactions with key amino acid residues, while also inducing conformational changes in the loop 1 region of the enzyme. Functionally, TH9028 slows down the progression of replication forks, induces replication stress, causes cell cycle arrest at the S phase, promotes apoptosis, inhibits thymidine synthesis, and leads to the misincorporation of uracil into DNA. In acute myeloid leukemia and T-ALL cells, TH9028 exhibits antiproliferative activity, while its effects on non-transformed cells are relatively weak. Therefore, TH9028 can be used in research related to acute myeloid leukemia.

JNJ-37822681 has potential for the treatment of schizophrenia and bipolar disorder.JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D2 receptor antagonist with a moderate binding affinity for the dopamine D2

TH7299 is an innovative and potent inhibitor of MTHFD1/D2/D2L, exhibiting stronger inhibitory effects on MTHFD1 and MTHFD2L.

RG-15 is an orally active dopamine receptor antagonist with high affinity for the human D2 receptor (pKi of 8.23) and human D3 receptor (pKi of 10.49). It inhibits dopamine-stimulated [35S]GTPγS binding with IC50 values of 21.2 nM in rat striatal membranes, 36.7 nM in mouse A9 cells expressing human D2L receptors, and 7.2 nM in CHO cells expressing human D3 receptors. RG-15 enhances dopamine turnover and synthesis in the striatum and olfactory bulb of mice, exhibiting antipsychotic activity.

Raxlaprazine etomoxil is a modulator of dopamine D2 and D3 receptors, applicable in psychiatric disorder research. It exhibits a Ki of 1.95 nM for human recombinant D2L receptors and an EC50 of 3.72 nM for forskolin-stimulated cAMP accumulation.

Perphenazine-D4 is a deuterated compound of Perphenazine. Perphenazine (T1090) has a CAS number of 58-39-9. Perphenazine (T1090) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.

Didesmethyl cariprazine-d8 is a deuterium-labeled version of Didesmethyl cariprazine, an orally active metabolite of Cariprazine capable of crossing the blood-brain barrier. It acts as a partial agonist at D2 and D3 receptors and a full agonist at the 5-HT1A receptor, while serving as an antagonist for the human 5-HT2B receptor. Its binding affinities are Ki: 1.41 nM for human D2L, 0.056 nM for human D3, 1.7 nM for human 5-HT1A, and 0.52 nM for human 5-HT2B. Didesmethyl cariprazine also dose-dependently suppresses the spontaneous activity of midbrain dopaminergic neurons in rats.

Perphenazine (Standard) is the standard substance of Perphenazine, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Perphenazine (Trilafon) is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.

Perphenazine-D4 (Standard) is a reference standard of Perphenazine-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Perphenazine-d4 is a deuterated compound of Perphenazine. Perphenazine has a CAS number of 58-39-9. Perphenazine is a phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties.